Company intelligence
Telomir Pharmaceuticals, Inc.
A novel small molecule is being developed as the first regulator of telomere length and genomic stability.
Biotechnology Research
Tampa, US
5 employees
Founded 2022
1 public signals
About Telomir Pharmaceuticals, Inc.
A novel treatment uniquely and selectively binds critical metals to interrupt enzyme function, returning cellular metals like Iron, copper, and zinc to homeostasis and turning off the underlying cause of cancer development and growth. By targeting specific classes of enzymes through its metal binding properties, Telomir 1 is believed to selectively affect the key processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.
Verified activity
Signals from Telomir Pharmaceuticals, Inc.
1 published signal